Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

AstraZeneca (AZN) Takeover Rumors, Response Genetics (RGDX) Enters Next Generation Sequencing Market

|Includes:AZN, Response Genetics, Inc. (RGDX) AstraZeneca PLC (NYSE:AZN)

Keep a close eye on AZN. According to reports, Pfizer has approached AZN to propose a $100 billion takeover.

AZN is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

More about AstraZeneca PLC (AZN) at

** Crown Equity Holdings Inc. (OTCPK:CRWE)

CRWE is currently developing its CRWE Network (, a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

The CRWE Network's business model is based on selling advertising to local businesses. It has recently added the communities of Zephyr Cove (, located in Douglas County, Nevada and Kelowna (, a city located in the Okanagan Valley of British Columbia, Canada.

Update: The CRWE Network has reached the 478th community website in the U.S., associated with 2003 ZIP Codes (includes coverage of the greater state of California, Northern and Southern Nevada and Wellington in Florida) and 10 provinces in Canada

The CRWE-PR's mobile marketing platform includes a coupon page for added readership and businesses value. The network offers business owners the power of consumer targeting advertisement on a local and national scale through offerings and deals with their restaurant, auto repair, realtor, bar, movie theater, retail business, golf course, auto dealership and any other variety of businesses existing within a community.

The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform ( The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (OTCPK:CRWE) at

** Response Genetics, Inc. (NASDAQ:RGDX)

Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs. These abnormal cells do not carry out the functions of normal lung cells and do not develop into healthy lung tissue. As they grow, the abnormal cells can form tumors and interfere with the functioning of the lung, which provides oxygen to the body via the blood.

Lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women (not counting skin cancer). In men, prostate cancer is more common, while in women breast cancer is more common. Lung cancer accounts for about 13% of all new cancers.

The American Cancer Society's estimates for lung cancer in the United States for 2014 are:

- About 224,210 new cases of lung cancer (116,000 in men and 108,210 in women)

- An estimated 159,260 deaths from lung cancer (86,930 in men and 72,330 among women), accounting for about 27% of all cancer deaths

RGDX reported an exclusive commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University (OHSU) for a proprietary next generation sequencing panel for lung cancer. The panel provides full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots.

The collaboration will leverage RGDX's national sales force and the Company expects to begin marketing the proprietary panel immediately.

With the addition of the OHSU next-generation sequencing panel for lung cancer, RGDX now offers oncologists and patients analyses of actionable genetic markers across six different tumor types and four different testing modalities.

RGDX is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.

More about Response Genetics, Inc. (RGDX) at


Read Full Disclaimer at

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Stocks: RGDX, AZN